The endocannabinoid system

Allyn Howlett and William Devane found the first cannabinoid receptor in rat brain tissue in 1988. They were not looking for a new body system. They were trying to answer a narrower question: THC is powerful at very small doses, which usually means a compound is binding to a specific receptor rather than dissolving into cell membranes at random. They went looking for the receptor and found it.

That receptor, now called CB1, was cloned by Lisa Matsuda's team in 1990. A second one, CB2, was cloned by Sean Munro's group in 1993. CB1 turned out to be one of the most abundant G-protein-coupled receptors in the mammalian brain, which raised an obvious problem. Evolution does not build a dense receptor network and wait several million years for a plant to come along and use it.

So there had to be something the body made itself. Devane and Raphael Mechoulam found it in 1992 and named it anandamide, from the Sanskrit ananda, meaning bliss. A second one, 2-arachidonoylglycerol or 2-AG, turned up in 1995. Both are built from arachidonic acid, a fatty acid already sitting in your cell membranes.

The shorthand is homeostasis, which is true and vague enough to be useless. The endocannabinoid system works as a dimmer switch on other signaling systems.

Most neurotransmitters travel forward, from the sending neuron across the synapse to the receiving one. Endocannabinoids travel backward. When a receiving neuron gets more signal than it wants, it synthesizes anandamide or 2-AG on the spot, sends them back across the synapse, and they bind CB1 on the sending neuron and tell it to ease off. This is called retrograde signaling, and it is why the same system can look like it does everything: appetite, pain perception, mood, memory, sleep, immune response, motor control. It regulates whatever else is driving them rather than driving any of them itself.

Two enzymes clear the messengers afterward. FAAH breaks down anandamide, MAGL breaks down 2-AG. Both work fast, which is why endocannabinoid signaling is local and short-lived rather than broadcast through the bloodstream like a hormone.

CB1 is dense in the brain, especially the hippocampus, basal ganglia, cerebellum and the areas handling pain and appetite. It is almost absent from the brainstem region controlling breathing, which is the accepted explanation for why cannabinoid overdose does not stop respiration the way opioid overdose does.

CB2 sits mostly outside the brain, on immune cells, in the spleen, in gut tissue and bone. THC binds CB1 directly and hard, which is what produces intoxication. Most other cannabinoids do not.

CBD binds CB1 and CB2 poorly. If receptor binding were the whole story, CBD would do almost nothing, and it plainly does something.

The current explanation is that CBD works around the receptors rather than through them. It appears to slow FAAH, the enzyme that clears anandamide, which leaves your own endocannabinoid in circulation longer. It also acts as a negative allosteric modulator at CB1, meaning it changes the shape of the receptor so THC binds less effectively. That second mechanism is the pharmacological basis for the common observation that CBD blunts the edge of THC.

CBD also hits targets outside the endocannabinoid system entirely: the serotonin 5-HT1A receptor, TRPV1 (the same channel capsaicin activates), and PPAR-gamma. Calling CBD a cannabinoid is accurate by origin and misleading by mechanism.

Three practical consequences follow from the biology.

First, individual variation is real and large. People differ in CB1 receptor density, in FAAH activity, and in baseline endocannabinoid levels. A dose that does nothing for one person can be plenty for another. This is why every honest dosing recommendation starts low and adjusts over a week or two instead of naming a number.

Second, different cannabinoids are not weaker or stronger versions of each other. CBG, CBC and CBD engage different targets. Swapping one for another changes what happens, not how much happens.

Third, timing matters more than milligrams for anything cumulative. Endocannabinoid signaling is a regulatory layer, and regulatory layers shift over days, not minutes.